We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Genetic Determinant Governs H Pylori Behavior

By Biotechdaily staff writers
Posted on 02 Jun 2006
Researchers have found that the ulcer-causing bacteria Helicobacter pylori requires a specific gene to be able to follow the pH gradient from the acidic reaches of the stomach to the more alkaline region of the gastric mucosa. More...
Mutants lacking this gene were unable to infect a line of susceptible mice.

Investigators at the University of Virginia (Charlottesville, USA) used a microscope slide-based pH gradient assay and video data collection system to document pH-tactic behavior. In response to hydrochloric acid, H pylori changed its swimming pattern from straight-line random swimming to arcing or circular patterns that moved the motile population away from the strong acid. Bacteria in more-alkaline regions did not swim toward the acid.

To identify the chemoreceptors responsible for the transduction of pH-tactic signals, genetic engineering was used to construct mutations in each of the four known chemoreceptor genes (tlpA, tlpB, tlpC, and tlpD) in H pylori strain SS1 and a motile variant of strain KE26695. Results of studies with these mutant strains published in the April 2006 edition of the Journal of Bacteriology revealed that only tlpB mutants were defective for pH taxis.

While tlpA, tlpC, and tlpD mutants were able to colonize mice to near wild-type levels, tlpB mutants failed to infect a line of highly permissive C57BL/6 mice. Replacement of tlpB restored both pH taxis and infectivity for mice.

"Because pH sensing ability is essential for colonization and persistence in the stomach lining tissue, the tlpB pH receptor might represent a novel target for the development of treatments that can interfere with this behavior,” said senior author Dr. Paul S. Hoffman, professor of infectious diseases at the University of Virginia. "H pylori infections occur most often in developing countries that cannot afford the cost of miracle drugs. Perhaps a narrow-spectrum drug designed to block the chemoreceptor would be less expensive to develop.”



Related Links:
University of Virginia

New
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
New
Gold Member
Automatic Hematology Analyzer
CF9600
New
Rapid Sepsis Test
SeptiCyte RAPID
New
Clinical Informatics Platform
CLARION™
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more

Molecular Diagnostics

view channel
Image: The new approach focuses on CpG DNA methylation, a chemical modification of cytosine and guanine bases, using tumor samples to develop a computational model that distinguishes among 21 cancer types (photo credet: 123RF)

Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary

Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.